Navigation Links
BioElectronics Corp. Announces $400,000 in New Orders From the Middle East
Date:9/18/2008

New Sales Agent and Distributor Gains Quick Traction in the Region

FREDERICK, Md., Sept. 18 /PRNewswire-FirstCall/ -- BioElectronics Corporation (BIEL) announced today that the new sales agent it announced last week, Abdulkader Al-Mehyar Moh'd Basheer Halawy has taken for approximately $400,000 in new sales in the Middle Eastern region.

"We are pleased that the new agent has hit the ground running and is finding wide marketing acceptance for our products. We look forward to significant repeat sales as the product is distributed throughout the territory," said Farid Tamimi V.P. of International Sales of BioElectronics Corporation. "There is strong demand for our inexpensive, drug-free medical products in the Middle East and other international markets."

BioElectronics Corporation (Pink Sheets: BIEL) is the maker of inexpensive, drug-free, anti-inflammatory medical devices and patches. The Company's inexpensive wafer thin patches and devices contain an embedded microchip and battery that deliver pulsed electromagnetic energy, a clinically proven and widely accepted anti-inflammatory and pain relief therapy that heretofore has only been possible to obtain from large, facility-based equipment. BioElectronics markets and sells its current products under the brand names ActiPatch(TM) and RecoveryRx(TM). The dermal patch delivery system creates a multitude of new product opportunities for chronic and acute inflammatory conditions.

For more information visit http://www.bioelectronicscorp.com or call 866-757-2284.

Information on ActiPatch and BioElectronics Corporation is available at the following websites:

-- Podiatry: http://www.pemfpodiatry.com

-- Plastic Surgery: http://www.plasticsurgeryrelief.com and http://www.makemeheal.com

-- German orthopedic foot & ankle: http://www.diesfussexperten.de

-- Italy and Switzerland: http://www.actipatch.it

-- Canada: http://www.actipatchpaintherapy.ca

-- Netherlands: http://www.actipatch.de

-- Singapore & Malaysia: http://www.astonixlife.com/

-- Denmark: http://www.c-m-a.dk

-- BioElectronics Corp: http://www.bioelectronicscorp.com

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

Contact:

Andrew J. Whelan

Andrew.Whelan@ActiPatch.net

BioElectronics Corporation

4539 Metropolitan Court

Frederick, MD 21704

866-757-2284 ext 107

301-874-4890 ext 107

301-874-6935 fax


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioElectronics Corporation Announces Singapore and Malaysia Sales
2. BioElectronics Corporation Announces Distribution Agreement With TSS Medical of Italy
3. BioElectronics Announces Canadian Retail Product Launch
4. BioElectronics Launches 1 Day Breast Augmentation Recovery Kit
5. BioElectronics Corporation Receives Major Orders From Italian Distributor
6. BioElectronics Announces Conference Call to Update Investors on Growth Initiatives
7. BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even
8. BioElectronics Announces Distribution Agreement for Sales In India
9. BioElectronics Corp Aggressively Expands Sales into Middle East
10. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
11. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):